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International strategic alliances of small biotechnology firms: a second-best option?
1. Literature review Dedicated Biotechnology Firms (DBFs) 1 almost invariably situate themselves in regional clusters where they are neighbours to large research universities and public laboratories.
Such institutions bring them the necessary ideas, personnel and incubation facilities to begin conducting R&D. The co-location of DBFs and research institutions is a universal phenomenon (Feldman, 2003; Lemarié et al., 2001; McKelvey et al., 2003; Niosi, 2005; Powell et al., 2002) . Many authors have mentioned that DBFs benefit from international strategic alliances, defined as a contractual agreement between at least two partners toward the achievement of a mutually beneficial goal, in a determined amount of time (Deeds and Hill, 1996; Coombs and Deed, 2000) . These goals may either be about one or more of the following functions: research and development, production or marketing. The agreement may also take different governance structures such as in-licensing, cooperation in R&D, out-licensing, joint ventures or mergers and acquisitions (Li et al., 2010) . They may be with universities or research institutes, other biotechnology or pharmaceutical firms (Baum et al., 2000) . Depending upon the required resources and capabilities, the size of the corporate partner may vary (Tyebjee and Hardin, 2004) . Strategic alliances increase small firm capabilities; they also provide new assets to DBFs, particularly complementary knowledge and financial resources Peng, 2000, GomesCasseres et al., 2006) . Strategic alliances allow smaller firms to access foreign capital and product markets, comply with different national drug regulations and conduct costly and complex clinical essays. In addition, the literature has observed that local networks of biotechnology firms tend to be more significant than international ones, and the opposite tends to be true when firms mature, and their project portfolio becomes more attractive 1 In its latest report, the OECD defined Dedicated Biotechnology Firms (DBFs) "as a biotechnology firm whose predominant activity involves the application of biotechnology techniques to produce goods or services and/or to perform biotechnology R&D" (Van Beuzekom and Arundel, 2009:10) . However, some disparities exist depending on the application fields of these technologies: health (human and animal), agrofood, natural resources, environment, industrial processing, and bioinformatics. Because of these different realities, the present study focus on human health biotechnology firms specialized "in the development, production, prescribing of therapeutics, in vivo diagnostics, and vaccines" (Van Beuzekom and Arundel, 2009:84) . 4 and valuable (Lemarié et al., 2001; Fontes, 2005) . R&D partnerships are the first step towards internationalization for DBFs (Veilleux et al., 2011) .
However, some scholars, if not a majority of them, have underscored the fact that not all strategic alliances are always successful, and some of them are neither beneficial nor detrimental (Kogut, 1989) . Thus, the search for factors explaining differential performance was launched (Gulati, 1995 and 1998) . Madhoc and Osegowitsch (2000) found that the country of origin is a key contextual factor shaping a firm's cooperation capabilities and competitiveness. It also shapes the industry through the availability of academic knowledge, public research funds and venture capital. Other authors have also found significant differences in the kind of international strategic alliances that DBFs tend to conclude based on the allies' country of origin (Fontes, 2005) . Lerner and Merges (2000) argued that early stage DBFs' strategic alliances may turn to the benefit of the stronger partner, particularly during periods of little financial activity.
For example, in the human health sector, strategic alliances with large pharmaceutical corporations are becoming the main source of financing for DBFs: "These periods are frequently termed 'buyer's markets'. The theoretical literature suggests that financing constraints may drive R&D firms to cede control rights in a buyer's market" (Lerner and Merges, 2000:127) .
Others found that strategic alliances were not the only, or even the most important factor for DBF growth (Niosi, 2003) . Similarly, Zollo et al. (2002) observed that strategic alliances performance in biotechnology depended on the partners' experience and, more specifically, on the smaller partners' experience. These authors conclude that strategic alliances are not always the panacea that the literature has often depicted.
In addition, venture-capital often appears as a key condition of growth. Baum and Silverman (2004) found that venture capital does more than "pick winners". It also builds up new firms by bringing them both capital and credibility. It is the second step, after patents, in the dynamic circle of growth in human health DBF (Niosi, 2003 In spite of the different funding opportunities, Canadian and US firms basically operate under similar patterns. The majority of them are university spin-offs, receive US and Canadian patents, obtain venture capital, develop products and sign strategic alliances with chemical or pharmaceutical corporations (Niosi and Bas, 2001; Niosi and Banik, 2005; Powell et al., 2002; Rothaermel and Deeds, 2006 In countries with smaller domestic markets, a smaller university system, and particularly those without a strong domestic pharmaceutical industry, DBFs are forced to go abroad to conduct R&D, production or marketing strategic alliances with large pharmaceutical firms (McKelvey et al., 2003; Gilding 2008; Veilleux et al., 2012) . American firms find complementary resources at home, while Canadian DBFs are forced to search for them in the international arena.
After the literature review, and based on previous findings, we draw the following propositions for our exploratory study in order to answer our main research question: Are international strategic alliances the best option for human health biotechnology firms?
Proposition 1: DBFs evolving in a scarce venture-capital home environment conduct international strategic alliances to overcome their lack of financial resources. The level of internationalization of biotechnology firms, as defined by the number of international strategic alliances, depends on country-specific characteristics: the smaller the home country of DBFs, the larger the number of international strategic alliances they breed.
Proposition 2: The timing of the first international strategic alliance is related to the availability of the home market venture-capital: the lower the amounts of venture-capital, the faster the entry into international strategic alliances. Boston firms compared to 69% for those in Montreal. Moreover, Bostonian firms received almost three times the median amount of venture-capital, and the amount of the IPO of those on the stock market was more than seven times higher.
( Table 1 here)
In Table 2 , the distribution of the 430 total strategic alliances was shown for both sets of firms, at the local and international levels. Table 3 describes all 430 strategic alliances in terms of goals, R&D partners' organization type, governance structure, and corporate partner size. They were then split into Table 4 and Table 5 , based on their locations.
While Table 4 characterizes the 180 local strategic alliances, Table 5 presents the 250 international strategic alliances. As show in Table 5 , the Montreal firms developed, on average, more R&D strategic alliances, 8.4 per firm against 6.5 for Boston companies.
Both at the local and international level, while R&D partners of Boston firms are corporate organizations, the Montreal firms collaborate more with universities. They also had more production and more marketing agreements. Boston's firms had more multifunctional agreements than Montreal's firms. Note that Montreal's firms have conducted more in-licensing agreements and R&D collaborations. Boston outperforms in outlicensing, mergers and multi-governance structure agreements.
( Tables 2, 3 As for the comparison between national and international strategic alliances in each cluster, Montreal firms register more international strategic alliances, regardless of the characteristics. As for Boston's firms, most of the agreements are more common in the home market, except for marketing strategic alliances, R&D partnerships with universities, and agreements with large firms.
While looking at the age of the firm at which the first international alliance occurred, overall, Montreal firms are active earlier in foreign markets. However, depending on the measure used (mean or median), this precocity is obvious in North America, probable in
Europe, but uncertain in Asia.
( Table 6 here)
Discussion
This study extended knowledge about the impact of the country of origin on firms' cooperation behaviour (Lemarié, 2001; Fontes, 2005) . Proposition 1 posits that DBFs evolving in a scarce venture-capital home environment conduct more international strategic alliances, which is consistent with our findings. DBFs in Boston and Montreal clusters have distinct profiles. There is a substantial difference between Boston and Montreal firms in terms of age, number of employees, percentages of firms that obtained venture capital and the amount raised, both from venture capital and IPOs. Thus, experience, financial and available human resources being very different for firms from these two regions, we could expect an impact on their business models and therefore, on their international strategic alliances' strategy.
Existing literature takes for granted that the more venture-capital a firm receives, the higher the number of international strategic alliances it will conclude, because the invested-in DBF has obtained the endorsement of the selective risk capital (Baum and 11 Silverman, 2004) . In our study, the opposite seems true. Boston DBFs in our sample prefer to remain at a distance from partners as long as possible, in order to increase the value of the incipient technology and avoid a sell-off situation. An explanation might be that strategic alliances can reduce revenues through profit sharing and expose themselves to possible opportunistic exploitation by their partners. On the other hand, in order to grow, in a context of scarce venture-capital, biotechnology firms use strategic alliances as an alternative source of seed capital.
Received knowledge (Hsu, 2006) However, when looking closely at the age at which they penetrate each continent, this international implication has its limitations. This might be explained by the required resources to meet and maintain relationships with partners that are in distant markets. The implication of this finding is that biotechnology firms do not necessarily need to conduct corporate strategic alliances early on, if they are able to find adequate support from angel and venture-capital or from capital markets during and after IPO (Ozmel et al., 2012) .
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They may prefer to "go it alone" before they request large corporate partners' financial and knowledge support.
Conclusion
This exploratory study was hoping to shed light on the impact of international strategic alliances in DBFs' growth, specifically in the human health sector, in an environment characterized by scant venture-capital. By examining two different clusters, namely
Boston and Montreal, it described how different DBFs' organizational characteristics and strategic alliances portfolio could be. It highlights the range of difference in the financing of Boston and Montreal firms and its impact on strategic alliance characteristics. Still being in the start-up stage, Montreal firms are multiplying R&D strategic alliances with universities and SMEs, while Boston firms with products at a later development stage can out-license their technologies and work with large firms. The age at which Montreal firms must internationalize and the extent to which they manage foreign partnerships are outstanding. International strategic alliances seem therefore to be a second-best option for firms evolving in an environment with scarce resources. Our exploratory study shows that international comparisons, especially between large and small size market countries, may uncover substantial differences in company strategy. On the northern side of the border, Montreal companies start their corporate partnering early, but do not grow faster or bigger under this type of environment. Boston biotechnology firms, on the contrary, seem more able to experience rapid grow in a setting of more abundant and more experienced venture-capital. Although these are preliminary results, international strategic alliances seem more critical for Montreal than for Boston firms.
Further research should verify these preliminary findings with larger samples in all main
Canadian and American human health biotechnology clusters allowing statistical analysis. Distinctive statistically valid samples of therapeutics and diagnostics firms could provide insights on different international alliance strategies and portfolios.
Comparison of other human health biotechnology clusters from both large and small Median number of international strategic alliances 2 3.5 Table 6 Internationalization Speed 
